Ezetyle P 4 Tablet contains Pitavastatin 4 mg and Ezetimibe 10 mg, a dual-action lipid-lowering combination formulated to support cholesterol control and cardiovascular health. The medicine combines the effects of a statin and a cholesterol absorption inhibitor to provide enhanced management of abnormal lipid levels. It is prescribed under medical supervision as part of a comprehensive approach that may include dietary changes, physical activity, and other lifestyle modifications.
Pitavastatin works by inhibiting HMG-CoA reductase, an enzyme responsible for cholesterol production in the liver, thereby reducing the formation of cholesterol in the body. Ezetimibe helps decrease intestinal absorption of cholesterol, limiting the amount of cholesterol entering the bloodstream. Together, these ingredients help lower LDL cholesterol and support improved lipid balance for patients requiring effective cholesterol management.
The tablet is commonly prescribed for hypercholesterolemia, mixed dyslipidemia, elevated LDL cholesterol levels, and cardiovascular risk management as advised by a healthcare professional. Regular treatment helps maintain healthier lipid levels and supports long-term cardiovascular care. The dosage and duration of therapy should be determined according to the patient's lipid profile, medical history, and treatment response.
With the increasing burden of lifestyle-related disorders, diabetes, obesity, and cardiovascular conditions, Ezetyle P 4 Tablet continues to hold strong importance in the lipid management segment. Its clinically established combination, physician trust, and growing demand for advanced cholesterol control solutions contribute to consistent market potential. The product offers valuable business opportunities and long-term growth prospects for retailers and distributors operating within the cardiovascular pharmaceutical sector.